NCT07437963 2026-03-18
Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse
National Cancer Institute (NCI)
Phase 1/2 Not yet recruiting
Clinical Trials
11 trialsNCT05583617 2026-03-06
PLYCOM
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT05434689 2026-03-05
COMMANDER
University of Alabama at Birmingham
Phase 1/2 Active not recruiting
NCT06232044 2026-03-04
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
Alliance for Clinical Trials in Oncology
Phase 1/2 Suspended
NCT05199311 2026-02-18
Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma
Hackensack Meridian Health
Phase 1/2 Recruiting
NCT06518551 2025-12-11
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT05392946 2025-10-29
Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study
Mayo Clinic
Phase 1/2 Active not recruiting
NCT06785415 2025-09-30
Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
Mayo Clinic
Phase 1/2 Recruiting
NCT02773030 2024-06-25
A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma
Celgene
Phase 1/2 Active not recruiting
NCT03310619 2024-04-04
PLATFORM
Celgene
Phase 1/2 Completed
NCT04882163 2021-10-05
Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
Celgene
Phase 1/2 Withdrawn